Exploring The Nexus: Methamphetamine-Induced Psychosis, Co-Morbid Mental Disorders, And Associated Risks Among Dependent Individuals In Tertiary Care Hospital Of Peshawar

• ORIGINAL ARTICLE | ISSUE DETAILS: VOL NO. 4 | ISSUE NO. 2

Abstract

Objective: This study examined the risk of lifetime and present methamphetamine-induced psychosis in dependent individuals. The relationship between methamphetamine-induced psychosis and mental co-morbidity was examined.

Study design : A Cross-sectional study

Duration and place of study : tertiary care hospital of Peshawar  from January 2022 to January 2023

Methods: This Cross-sectional study done simultaneously at a Peshawar Tartary  care hospital from January 2022 to January 2023. The Mini International Neuropsychiatric Interview (M.I.N.I.) was used to interview DSM-IV-diagnosed methamphetamine users for psychosis and other Axis I psychiatric disorders. Social demographics and drug use history were acquired via interviews or medical records.

Results: There was a history of psychotic symptoms in 65 (45.4% of the total) participants, and 23 (15.6% of the total) patients at the present time. After adjusting for other covariates, there was a substantial association between heavy methamphetamine use, childhood methamphetamine-induced psychosis, and co-morbid major depressive disorder (n-24, 16.2%), bipolar disorder (n-6, 5.8%), and antisocial personality disorder (n-14, 10.8%). The only variables linked to present psychosis were major depressive illness (n-6, 5.8% of the population) and antisocial personality disorder (n-4, 4.2% of the population).

Conclusion: this study sheds light on the interplay between methamphetamine use, psychosis, and co-morbid mental disorders. Early detection and integrated treatment approaches are vital for mitigating the adverse effects of substance abuse and improving mental health outcomes in affected individuals.